Luteolin

Promising preclinical anti-neuroinflammatory and mast cell-stabilizing properties, but human clinical data is sparse. Often used anecdotally for mast cell activation issues.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Luteolin inhibits NF-kB, reduces pro-inflammatory cytokine release, and stabilizes mast cells in vitro and animal models. Some clinical interest for neuroinflammatory conditions and autism (as a mast cell stabilizer). Bioavailability is low and enhanced by co-administration with quercetin or liposomal delivery.

• Potent mast cell stabilizer in vitro
• Anti-neuroinflammatory properties in preclinical models
• Antioxidant and anti-allergic activity

Supplement doses typically range from 100-400 mg daily. Often combined with quercetin or in liposomal formulations to improve absorption.

• GI discomfort
• Possible iron absorption interference
• Limited safety data at high doses

Limited human safety data at supplement doses. May interact with CYP enzymes. Potential iron chelation at high doses.

Most evidence is preclinical. Oral bioavailability is poor without enhanced delivery. Clinical trials are very few and mostly pilot-scale.

• Immunity30
• Anxiety22